（编辑 姚尧） 证券日报网讯 11月7日晚间，泓博医药发布公告称，2025年半年度权益分派方案为向全体股东每10股派 0.7元人民币现金（含税）。股权登记日为2025年11月13日，除权除息日为2025年11月14日。 ...

证券代码：301230 证券简称：泓博医药 公告编号：2025-063 上海泓博智源医药股份有限公司 2025年半年度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 特别提示： 总股本 139,586,605 股扣除回购专用账户中已回购股份后 137,540,405 股为基数测算，共 计派发现金股利约 9,627,828.35 元（含税）。若在本利润分配方案实施前公司总股本发 生变动，公司将按照分配比例不变的原则对分配总额进行调整。 2、自分配方案披露至实施期间，本公司股本总额未发生变化。因公司实施回购方 案，公司回购专用账户持有的 2,046,200 股不参与本次利润分配。 1、上海泓博智源医药股份有限公司（以下简称"公司"或"本公司"）回购专用 证券账户中的股份 2,046,200 股不参与本次权益分派。公司 2025 年半年度权益分派方案 为：以公司现有总股本 139,586,605 股扣除回购专用账户中已回购股份 2,046,200 股后的 137,540,405 股为基数，向全体股东每 10 股派发现金红利 0.7 元（含税），送红 ...

Group 1 - The CRO index experienced fluctuations and a downward trend on November 4th [1] - Among the constituent stocks, Shengnuo Bio, Hongbo Pharmaceutical, and Chengdu XianDao had the largest declines, with decreases of 3.80%, 3.79%, and 3.53% respectively [1]

Core Viewpoint - On November 3, a total of 12 listed companies will have their restricted shares unlocked, with a total market value of approximately 8.307 billion yuan [1] Summary by Category Restricted Share Unlocking Details - Yunding Technology (Stock Code: 000409) will unlock 153 million shares from a private placement of A-shares [1] - China Unicom (Stock Code: 600050) will unlock 250 million shares related to equity incentive restrictions [1] - Ningbo Yunsheng (Stock Code: 600366) will unlock 5.857 million shares from equity incentives [1] - Changrun Co., Ltd. (Stock Code: 603201) will unlock 387,500 shares from equity incentives [1] - Lingda Co., Ltd. (Stock Code: 300125) will unlock 630,000 shares from equity incentives [1] - Wanda Information (Stock Code: 300168) will unlock 1.2701 million shares from equity incentives [1] - Qunxing Toys (Stock Code: 002575) will unlock 7.2 million shares from equity incentives [1] - Lushan New Materials (Stock Code: 603051) will unlock 391,200 shares from equity incentives [1] - Hongbo Pharmaceutical (Stock Code: 301230) will unlock 4.8251 million shares from pre-issue restrictions [1] - Oppein Home (Stock Code: 603551) will unlock 60,000 shares from equity incentives [1] - Yihe Jiaye (Stock Code: 301367) will unlock 2.34362 million shares from pre-issue restrictions [1] - Ruina Intelligent (Stock Code: 301129) will extend the lock-up period for 8.8992 million shares [1]

Core Viewpoint - On November 3, a total of 7 companies had their restricted shares unlocked, with a total unlock volume of 242 million shares, amounting to a market value of 4.354 billion yuan based on the latest closing prices [1] Summary by Category Unlock Volume - The companies with the highest unlock volumes are Yunding Technology, Hongbo Pharmaceutical, and Ruina Intelligent, with unlock shares of 153 million, 48.755 million, and 28.917 million shares respectively [1] Unlock Market Value - In terms of unlock market value, Yunding Technology, Hongbo Pharmaceutical, and Ruina Intelligent lead with market values of 1.74 billion yuan, 1.686 billion yuan, and 748 million yuan respectively [1] Unlock Ratio - The companies with the highest unlock ratios relative to their total share capital are Hongbo Pharmaceutical, Yunding Technology, and Ruina Intelligent, with unlock ratios of 34.93%, 22.61%, and 21.28% respectively [1]

Group 1 - A total of 7 companies had their restricted shares unlocked on November 3, with a combined unlock volume of 242 million shares, valued at 4.354 billion yuan based on the latest closing prices [1] - The companies with the highest unlock volumes are Yunding Technology, Hongbo Pharmaceutical, and Ruina Intelligent, with unlock shares of 153 million, 48.76 million, and 28.92 million respectively [1] - In terms of unlock value, Yunding Technology, Hongbo Pharmaceutical, and Ruina Intelligent lead with unlock values of 1.74 billion yuan, 1.686 billion yuan, and 748 million yuan respectively [1] - The highest percentage of total share capital unlocked is seen in Hongbo Pharmaceutical, Yunding Technology, and Ruina Intelligent, with unlock ratios of 34.93%, 22.61%, and 21.28% respectively [1]

Core Viewpoint - Hongbo Pharmaceutical (301230.SZ) has signed a supplementary agreement to extend the action agreement among its actual controllers until October 31, 2025, reflecting confidence in the company's long-term development and aiming to enhance operational decision-making efficiency [1] Group 1 - The supplementary agreement to the action agreement among Ping Chen, An Rongchang, and Jiang Shengli will expire on October 31, 2025 [1] - The voting rights entrustment relationship between shareholders of Pharma Resources Holding Co., Ltd. and Ping Chen will also expire on October 31, 2025 [1] - The parties involved have signed a new supplementary agreement to extend the action relationship, ensuring the company's stable development [1] Group 2 - Hongjian Zhang and Michael Gao have recently signed revised voting rights entrustment agreements with Ping Chen to extend their voting rights relationship [1] - The voting rights entrustment relationship between Genesis and Ping Chen will not be renewed [1]

Group 1 - The core viewpoint of the report is that Hongbo Pharmaceutical (301230.SZ) is rated as "Buy" due to its strong Q3 revenue growth and rapid profit recovery year-on-year [1] - The report highlights a significant improvement in profit margins year-on-year, along with optimized sales and R&D expense ratios [1] - There is a gradual recovery in overseas demand, and the company is entering a phase of rapid volume growth [1]

Core Viewpoint - The company reported strong revenue growth and significant profit recovery in the third quarter of 2025, driven by the gradual recovery of overseas demand and optimized cost management [1][2]. Financial Performance - For the first three quarters of 2025, the company achieved revenue of 514 million, a year-on-year increase of 31.43%, and a net profit attributable to shareholders of 35 million, up 127.96%. The net profit after deducting non-recurring items was 28 million, reflecting a growth of 353.43% [1]. - In Q3 2025, the company recorded revenue of 162 million, a year-on-year growth of 28.67%, and a net profit of 9.99 million, marking a turnaround from loss to profit compared to the same period last year [2]. Profitability Metrics - The gross margin for the first three quarters of 2025 was 28.05%, an increase of 4.29 percentage points year-on-year, while the net margin was 6.76%, up 2.87 percentage points [2]. - The company optimized its sales and R&D expense ratios, which were 1.90% and 5.60% respectively, down 0.56 and 3.57 percentage points from the previous year [2]. Market Outlook - The company anticipates a recovery in overseas business due to the easing of monetary policy by the Federal Reserve and a rebound in overseas investment and demand [2]. - The commercial production business is expected to enter a rapid growth phase following the expiration of patent protection for a key product in December 2024, leading to increased overseas demand [2]. Earnings Forecast - Revenue projections for 2025-2027 are 739 million, 989 million, and 1.299 billion, with year-on-year growth rates of 35.79%, 33.79%, and 31.34% respectively. Net profits are forecasted at 47 million, 64 million, and 99 million, corresponding to PE ratios of 100, 72, and 47 [3].

证券代码：301230 证券简称：泓博医药 公告编号：2025-062 上海泓博智源医药股份有限公司 关于实际控制人一致行动关系续期及间接控股股东部分上层股东 表决权委托续期的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 上海泓博智源医药股份有限公司（以下简称"公司"）实际控制人 Ping Chen 先生、 安荣昌先生、蒋胜力先生（以下简称"各方"）签署的《一致行动人协议之补充协议》 于 2025 年 10 月 31 日到期。同时，公司间接控股股东 PharmaResources Holding Co.,Ltd. （以下简称"泓博控股"）之股东 Hongjian Zhang、MICHAEL GAO、Genesis Ventures Investments Limited（以下简称"Genesis"）与 Ping Chen 先生之间的关于泓博控股的表 决权委托关系亦于 2025 年 10 月 31 日到期。 基于对公司长远发展的信心，同时为保障公司持续、稳定发展，提高公司经营决策 效率，各方于 2025 年 10 月 31 日签署了《一致行动人协议之补充 ...